Clinical Trial

Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)

Study acronym: KESETT
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to determine if treatment of patients with two doses of ketamine plus levetiracetam versus levetiracetam alone leads to more effective control of status epilepticus.
Protocol Amendment History 2 changes
notable Trial sites expanded: 47 -> 51 locations 2026-04-21
notable Trial sites expanded: 31 -> 47 locations 2026-04-10
Trial Details
NCT Number NCT06907173
Lead Sponsor University of Virginia
Collaborators: University of Michigan, Medical University of South Carolina, Massachusetts General Hospital, Children's National Research Institute
Conditions Status Epilepticus
Enrollment 770 participants
Start Date 2026-03-06
Primary Completion 2029-06 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-14